LCM
TEVA icon

Lazari Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Lazari Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356K Buy
10,507
+4
+0% +$133 0.11% 116
2026
Q1 		$316K Sell
10,503
-556
-5% -$17.9K 0.11% 113
2025
Q4 		$345K Sell
11,059
-400
-3% -$9.85K 0.12% 107
2025
Q3 		$231K Sell
11,459
-87
-0.8% -$1.53K 0.08% 137
2025
Q2 		$194K Sell
11,546
-2,809
-20% -$45.3K 0.07% 142
2025
Q1 		$221K Sell
14,355
-153
-1% -$2.73K 0.09% 129
2024
Q4 		$320K Sell
14,508
-1,102
-7% -$20K 0.13% 94
2024
Q3 		$281K Hold
15,610
– – 0.12% 110
2024
Q2 		$254K Sell
15,610
-120
-0.8% -$1.85K 0.11% 107
2024
Q1 		$222K Sell
15,730
-500
-3% -$6.3K 0.12% 98
2023
Q4 		$169K Sell
16,230
-900
-5% -$8.4K 0.1% 109
2023
Q3 		$175K Sell
17,130
-1,200
-7% -$11.2K 0.1% 105
2023
Q2 		$138K Buy
+18,330
New +$149K 0.08% 115

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Lazari Capital Management's TEVA Position: Q2 2026 in Review

Lazari Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 0.04% in Q2 2026, buying an estimated $133 and bringing the position to 10,507 shares worth $356K. The position accounts for 0.11% of the portfolio, ranked #116.

Lazari Capital Management first reported a position in TEVA in Q2 2023 and has held it in 13 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Lazari Capital Management held 10,507 shares of Teva Pharmaceuticals worth $356K as of Q2 2026.
  • Lazari Capital Management bought 4 Teva Pharmaceuticals shares in Q2 2026, an estimated $133.
  • Teva Pharmaceuticals made up 0.11% of Lazari Capital Management's portfolio in Q2 2026, its #116 holding.
  • Lazari Capital Management first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Lazari Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.